Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma

Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma

Abstract: Multiple myeloma (MM) remains incurable, with poor outcomes in heavily pretreated patients. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment; however, outcomes after such therapy in patients with soft-tissue plasmacytomas and other bone lesions remain poo...

Full description

Saved in:
Bibliographic Details
Main Authors: Inés Zugasti, Marta Tormo-Ratera, Aina Oliver-Caldés, Juan Carlos Soler-Perromat, Verónica González-Calle, David F. Moreno, Valentín Cabañas, Nieves López-Muñoz, Álvaro Bartolomé-Solanas, Marta Español-Rego, Juan Luis Reguera-Ortega, Laura Rosiñol, Lucía López-Corral, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, Rosa Maria Alvarez Perez, Sara Varea, Eulàlia Olesti, Adolfo Gomez-Grande, Laura Frutos, Pilar Tamayo, Manel Juan, José M. Moraleda, Álvaro Urbano-Ispizua, E. Azucena González-Navarro, Joaquín Martínez-López, Maria-Victoria Mateos, Xavier Tomás, Xavier Setoain, Carlos Fernández de Larrea
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952924006797
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2473952924006797

Similar Items